Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study

International Journal of Rheumatic Diseases

Volumn 19, Issue 11, 2016, Pages 1093-1102

  Pascart, Tristan ^a,b   Philippe, Peggy ^b   Drumez, Elodie ^a   Deprez, Xavier ^c   Cortet, Bernard ^b   Duhamel, Alain ^a   Houvenagel, Eric ^a   Flipo, René Marc ^b  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c CENTRE HOSPITALIER DE VALENCIENNES   (France)

Author keywords

abatacept; biologics failure; rheumatoid arthritis; rituximab; tocilizumab

Indexed keywords

ABATACEPT; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; RITUXIMAB; TOCILIZUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; BIOLOGICAL PRODUCT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DAS28; DRUG EFFICACY; DRUG TREATMENT FAILURE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; AGED; ARTHRITIS, RHEUMATOID; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG SUBSTITUTION; FRANCE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT FAILURE;

ABATACEPT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; BIOMARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; DRUG SUBSTITUTION; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RITUXIMAB; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT FAILURE;

EID: 84961718582     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12845     Document Type: Article

References (30)

1. Smolen JS, Landewé R, Breedveld FC et al. (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69, 964–75.
2. Cohen SB, Emery P, Greenwald MW et al. (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54, 2793–806.
3. Schiff M, Keiserman M, Codding C et al. (2008) Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67, 1096–103.
4. Genovese MC, Schiff M, Luggen M et al. (2008) Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 67, 547–54.
5. Jones G, Sebba A, Gu J et al. (2010) Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69, 88–96.
6. Emery P, Keystone E, Tony HP et al. (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67, 1516–23.
7. Smolen JS, Landewé R, Breedveld FC et al. (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73, 492–509.
8. Gaujoux-Viala C, Gossec L, Cantagrel A et al. (2014) Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis. Joint Bone Spine 81, 287–97.
9. Gomez-Reino JJ, Maneiro JR, Ruiz J et al. (2012) Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study. Ann Rheum Dis 71, 1861–4.
10. Emery P, Gottenberg JE, Rubbert-Roth A et al. (2014) Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis 74, 979–84.
11. Favalli EG, Biggioggero M, Marchesoni A, Meroni PL (2014) Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology (Oxford) 53, 1664–8.
12. Das S, Vital EM, Horton S et al. (2014) Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. Ann Rheum Dis 73, 909–12.
13. Aletaha D, Neogi T, Silman AJ et al. (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69, 1580–8.
14. Prevoo ML, van't Hof MA, Kuper HH et al. (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38, 44–8.
15. Wells G, Becker J-C, Teng J et al. (2009) Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 68, 954–60.
16. LaVange LM, Koch GG (2006) Rank score tests. Circulation 114, 2528–33.
17. Frazier-Mironer A, Dougados M, Mariette X et al. (2014) Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice. Joint Bone Spine 81, 352–9.
18. Singh JA, Wells GA, Christensen R et al. (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2, CD008794. doi: 10.1002/14651858.CD008794.pub2.
19. Moshage HJ, Roelofs HM, van Pelt JF et al. (1988) The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. Biochem Biophys Res Commun 155, 112–7.
20. Nishimoto N, Terao K, Mima T et al. (2008) Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112, 3959–64.
21. Gabay C, Emery P, van Vollenhoven R et al. (2013) Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381, 1541–50.
22. Weinblatt ME, Schiff M, Valente R et al. (2013) Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 65, 28–38.
23. Nam JL, Ramiro S, Gaujoux-Viala C et al. (2014) Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 73, 516–28.
24. Singh JA, Christensen R, Wells GA et al. (2009) Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2, CD007848. doi: 10.1002/14651858.CD007848.
25. Guyot P, Taylor PC, Christensen R et al. (2012) Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom. J Rheumatol 39, 1198–206.
26. Bergman GJD, Hochberg MC, Boers M et al. (2010) Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 39, 425–41.
27. Leffers HC, Ostergaard M, Glintborg B et al. (2011) Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 70, 1216–22.
28. Manders SH, Kievit W, Adang E et al. (2015) Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. Arthritis Res Ther 22 (17), 134.
29. Buch MH, Boyle DL, Rosengren S et al. (2009) Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 68, 1220–7.
30. Cohen J (1992) A power primer. Psychol Bull 112, 155–9.